CARL WHEELER: Open Payments
NPI 1134161425 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$423 in 18 payments from 11 companies in 2025. Trend: 2023 $34 · 2024 $0 · 2025 $423
Food & beverage: $423
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $91 |
| Madrigal Pharmaceuticals | 2 | $66 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Novo Nordisk Inc | 1 | $28 |
| QOL Medical, LLC | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Digestive Care, Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| PFIZER INC. | 1 | $23 |
Products named: TREMFYA, REZDIFFRA, VOQUEZNA, Wegovy, Sucraid, DUPIXENT, Pertzye, XIFAXAN.
Industry payments across MD — which companies pay providers there.
